Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

NCT00358293 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Spasticity

Interventions

DRUG: Tizanidine (sublingual or oral)

Sponsor

Teva GTC